Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27548466)

Published in Bone Marrow Transplant on August 22, 2016

Authors

Z DeFilipp1, R F Duarte2, J A Snowden3, N S Majhail4, D M Greenfield5, J L Miranda6, M Arat7, K S Baker8, L J Burns9, C N Duncan10, M Gilleece11, G A Hale12, M Hamadani13, B K Hamilton4, W J Hogan14, J W Hsu15, Y Inamoto16, R T Kamble17, M T Lupo-Stanghellini18, A K Malone19, P McCarthy20, M Mohty21,22,23, M Norkin15, P Paplham20, M Ramanathan24, J M Richart25, N Salooja26, H C Schouten27, H Schoemans28, A Seber29,30, A Steinberg19, B M Wirk31, W A Wood32, M Battiwalla33, M E D Flowers8, B N Savani34, B E Shaw13

Author Affiliations

1: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
2: Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
3: Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.
4: Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
5: Specialized Cancer Services, Sheffield Teaching Hospital NHS Foundation Trust, Shefflied, UK.
6: Department of Medicine, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research at Cordoba (IMIBIC), University of Cordoba, CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
7: Florence Nightingale Sisli Hospital, Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey.
8: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
9: National Marrow Donor Program, University of Minnesota, Minneapolis, MN, USA.
10: Pediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Boston, MA, USA.
11: Leeds Teaching Hospitals NHS Trust, Leeds, UK.
12: All Children's Hospital, John Hopkins Medicine, St. Petersburg, FL, USA.
13: Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
14: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
15: Division of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
16: Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
17: Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
18: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
19: Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
20: Department of Medicine, Roswell Park Cancer Institute, BMT Program, Buffalo, NY, USA.
21: University Pierre & Marie Curie, Paris, France.
22: Hopital Saint-Antoine, AP-HP, Paris, France.
23: INSERM UMRs 938, Paris, France.
24: Department Hematology, Oncology and Bone Marrow Transplant, UMass Memorial Medical Center, Worcester, MA, USA.
25: Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA.
26: Hammersmith Hospital, London, UK.
27: Maastricht University Medical Center, Maastricht, The Netherlands.
28: Department of Hematology, University Hospital Leuven and KU Leuven, Leuven, Belgium.
29: Hospital Samaritano, Sao Paulo, Brazil.
30: Associação da Medula Ossea - AMEO, Sao Paulo, Brazil.
31: Department of Internal Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA.
32: Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
33: Hematology Branch, National Institutes of Health, Bethesda, MD, USA.
34: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Articles cited by this

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 118.65

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 95.79

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74

Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA (2014) 36.94

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation (2009) 35.24

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA (2014) 34.12

Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76

Diagnosis and classification of diabetes mellitus. Diabetes Care (2010) 28.34

Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21

The metabolic syndrome--a new worldwide definition. Lancet (2005) 23.51

Abdominal obesity and metabolic syndrome. Nature (2006) 14.20

Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 14.03

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood (2005) 10.63

Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet (2012) 6.81

Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet (2012) 4.33

Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke (2008) 4.28

Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2015) 4.11

Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood (2007) 3.87

Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health (2013) 3.82

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

A comprehensive review on metabolic syndrome. Cardiol Res Pract (2014) 3.47

Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet (2000) 3.39

Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood (2010) 2.34

Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation (2007) 2.26

Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke (2006) 2.24

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20

Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood (2006) 2.20

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11

Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull (2010) 2.09

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood (2005) 2.04

Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer (2006) 1.97

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2006) 1.87

Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood (2011) 1.71

Deaths: leading causes for 2007. Natl Vital Stat Rep (2011) 1.67

Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood (2007) 1.67

Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med (2013) 1.64

Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood (2012) 1.58

Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46

Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant (2013) 1.30

High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2008) 1.27

Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med (2011) 1.23

Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant (2008) 1.20

Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig (2013) 1.13

Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.08

Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood (2010) 1.08

Hyperinsulinemia in children and adolescents after bone marrow transplantation. Bone Marrow Transplant (1995) 1.07

Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant (2011) 1.05

Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant (2010) 1.03

National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant (2012) 1.01

[Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2013) 1.00

Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.00

Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol (2013) 0.99

Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol (2013) 0.98

Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation. J Pediatr (2011) 0.96

Body composition assessment for the definition of cardiometabolic risk. J Endocrinol Invest (2013) 0.96

Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant (2014) 0.93

Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. Haematologica (2010) 0.93

Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study. Bone Marrow Transplant (2009) 0.93

Etiology of stroke in children. J Child Neurol (1993) 0.91

Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. Bone Marrow Transplant (2005) 0.90

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.90

Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. J Hypertens (2010) 0.88

Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract (2010) 0.86

Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk (2015) 0.85

Hypertriglyceridemia and its pharmacologic treatment among US adults--invited commentary. Arch Intern Med (2009) 0.85

Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 0.83

Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. Clin Transplant (2012) 0.83

Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation. Pediatr Blood Cancer (2015) 0.83

The relation of metabolic syndrome according to five definitions to cardiovascular risk factors--a population-based study. BMC Public Health (2009) 0.81

Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes. Pediatr Blood Cancer (2015) 0.81

Adverse Fat Depots and Marrow Adiposity Are Associated With Skeletal Deficits and Insulin Resistance in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation. J Bone Miner Res (2015) 0.80

Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology (2013) 0.79

Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents. Pediatr Blood Cancer (2012) 0.79

[Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study]. Rev Esp Cardiol (2011) 0.79

Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood (2014) 0.79

Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplant (2014) 0.79

Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study. Bone Marrow Transplant (2015) 0.79

Cerebral vascular abnormalities in pediatric patients with sickle cell disease after hematopoietic cell transplant. J Pediatr Hematol Oncol (2014) 0.78

Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies. Int J Hematol (2014) 0.78

Metabolic syndrome appears early after hematopoietic cell transplantation. Metab Syndr Relat Disord (2014) 0.77

Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant (2014) 0.77

Progressive multifocal cerebral infarction in a young kidney transplant recipient due to thrombotic microangiopathy. BMC Nephrol (2014) 0.77

Primary prevention of CVD: treating dyslipidaemia. BMJ Clin Evid (2008) 0.76

Reversible cerebral vasoconstriction syndrome resulted in cerebral infarction after allogeneic stem cell transplantation: a case report. Ann Hematol (2013) 0.76

Metabolic syndrome in hematologic malignancies survivors: a meta-analysis. Med Oncol (2014) 0.76

Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. Eur J Prev Cardiol (2014) 0.76

Articles by these authors

Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant (2015) 0.86

Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone Marrow Transplant (2014) 0.85

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant (2015) 0.83

Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. Bone Marrow Transplant (2016) 0.79

Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant. Bone Marrow Transplant (2013) 0.79

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant (2015) 0.79

Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant (2016) 0.77

A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant (2015) 0.77

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant (2015) 0.77

The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant (2016) 0.77

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. Bone Marrow Transplant (2016) 0.75

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant (2016) 0.75

Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. Bone Marrow Transplant (2015) 0.75

Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy. Bone Marrow Transplant (2016) 0.75

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone Marrow Transplant (2016) 0.75

GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant (2017) 0.75

Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. Bone Marrow Transplant (2017) 0.75

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant (2017) 0.75

A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant (2017) 0.75

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. Bone Marrow Transplant (2016) 0.75